前列腺癌
聚ADP核糖聚合酶
PARP抑制剂
临床试验
医学
肿瘤科
内科学
前列腺
癌症
癌症研究
生物
遗传学
DNA
聚合酶
作者
Juliet Carmichael,Ines Figueiredo,Bora Gürel,Nick Beije,Wei Yuan,Jan Rekowski,George Seed,Suzanne Carreira,Cláudia Bertan,Maria D. Fenor de la Maza,Khobe Chandran,Antje Neeb,Jon Welti,Lewis Gallagher,Denisa Bogdan,Mateus Crespo,Ruth Riisnaes,Ana Ferreira,Susana Miranda,Jinqiu Lu
摘要
BACKGROUND. Clinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). RNASEH2B loss is unrelated to HRD and preclinically sensitizes to PARP inhibition. The current study reports on RNASEH2B protein loss in advanced prostate cancer and its association with RB1 protein loss, clinical outcome and clonal dynamics during treatment with PARP inhibition in a prospective clinical trial.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
不想干活
小花排草
CAOHOU
xzy998
继续加油吧
pishuang
天堂之光
飲啖茶食個包
微笑绿旋
子车茗
Wind
HZQ
Zoo
pluto
乌萨奇
ED
高贵熊猫
善良的梦槐
pcr163
yydragen
皖公网安备34019202002308
